Auburndale, MA, United States of America

Jonathan Harry Davis

This inventor holds 36 USPTO granted patents and 11 published patent applications and 14 EPO patents, primarily in Biotechnology Innovations. Top assignees: Bristol-Myers Squibb Compnay, Merck Patent Gmbh, Pride Mobility Products Corporation. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jonathan Harry Davis. Retrieved from https://idiyas.com/inventor/jonathan-harry-davis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 (Patent Applications = 11)

% Patents Active = 100.0

EPO Patents = 14 (Patent Applications = 16)

Average Co-Inventor Count = 2.9

ph-index = 8

Forward Citations = 299(Granted Patents)

Location History:

Exeter, PA (US) (2015)
Waltham, MA (US) (2019 - 2021)
Madison, WI (US) (2020 - 2022)
Auburndale, MA (US) (2013 - 2024)
Nanticoke, PA (US) (2022 - 2024)

Company Filing History:

22 out of 3,737

Bristol-Myers Squibb Compnay

Pride Mobility Products Corporation

patents

4. 2 out of 45

Viiv Healthcare UK (No.5) Limited

patents

5. 1 out of 41

Bristol Meyers Squibb Company

patents

6. 1 out of 268

Cancer Research Technology Limited

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Fibronectin Proteins

Immunogenicity Reduction

Heterodimerization

Interleukin-2

CD19 Antibodies

Scaffold Proteins

HIV Fusion Polypeptides

Fc Fusion Proteins

Mobility Vehicles

Dystrophins

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12680108 - MINIATURIZED DYSTROPHINS AND USES THEREOF (2026-07-14),

2. 12534511 - SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS (2026-01-27),

3. 12440405 - Mobility vehicle (2025-10-14),

4. 12312418 - Orthogonal mutations for heterodimerization (2025-05-27),

5. 12202872 - Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use (2025-01-21),

6. 12076284 - Mobility vehicle (2024-09-03),

7. 11858979 - Fibronectin based scaffold domain proteins that bind PCSK9 (2024-01-02),

8. 11535868 - Miniaturized dystrophins having spectrin fusion domains and uses thereof (2022-12-27),

9. 11447538 - Fibronectin based scaffold proteins (2022-09-20),

10. 11419774 - Mobility vehicle (2022-08-23),

11. 11408093 - Fibronectin binding domains with reduced immunogenicity (2022-08-09),

12. 11359000 - Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use (2022-06-14),

13. 11279751 - Fibronectin binding domains with reduced immunogenicity (2022-03-22),

14. 11208496 - Anti-CD19 antibodies with reduced immunogenicity (2021-12-28),

15. 11203630 - Serum albumin-binding fibronectin type III domains (2021-12-21),

Title: Inventor Jonathan Harry Davis

Introduction: Jonathan Harry Davis is a prolific inventor based in Auburndale, MA (US) known for his groundbreaking contributions to various industries.

Latest Patents: Jonathan Harry Davis holds several patents in the fields of technology, healthcare, and consumer products, showcasing his diverse range of innovative ideas.

Career Highlights: Throughout his career, Jonathan Harry Davis has demonstrated a keen ability to identify gaps in the market and develop unique solutions to address them. His inventions have significantly impacted the way people interact with technology and have improved various aspects of daily life.

Collaborations: Jonathan Harry Davis has collaborated with leading companies and research institutions to bring his inventions to life. His partnerships have been instrumental in turning his ideas into tangible products that benefit society.

Conclusion: Jonathan Harry Davis continues to push the boundaries of innovation, and his passion for creating meaningful change through his inventions is truly inspiring.

Profile summary based on public USPTO records.